Human medicines European public assessment report (EPAR): Ritonavir Viatris (previously Ritonavir Mylan), ritonavir, Date of authorisation: 09/11/2017, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 13, Status: Authorised

Orphan designation: somapacitan Treatment of growth hormone deficiency, 24/08/2018 Withdrawn

Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Thiotepa Riemser, thiotepa, Date of authorisation: 26/03/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Scenesse, afamelanotide, Date of authorisation: 22/12/2014, Revision: 14, Status: Authorised

PSUSA/00001204/202602

PSUSA/00009057/202601

Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Date of authorisation: 19/06/2026, Revision: 1, Status: Authorised